BioXyTran, Inc. — Tissue Regeneration for Life
Bioxytran Inc. (OTC: BIXT) is a late stage biotechnology company that is developing a first-in-class oxygen treatment platform for victims of brain stroke trauma.
The company’s lead drug candidate, BXT-25, is getting ready to proceed to testing. BXT-25 has many properties of an existing, well tested drug, called Hemopure, that came off patent in 2016. BXT-25 contains Hemopure’s building block plus Bioxtytran’s specialized intellectual property which has resulted in an improved formulation, expected to yield better safety and efficacy profile than its parent. The drug will be evaluated as a resuscitative agent to treat strokes, especially during the all-critical first hour following a stroke. The product will also be evaluated for its efficacy in treating other brain trauma issues.
Bioxtytran’s technology is based upon the transportation of oxygen through its lead compound BXT-25, a nanoscale oxygen carrier that is 5,000 times smaller than a red blood cell. Accordingly, BXT-25 penetrates deep into hypoxic tissues to deliver the right type of oxygen, which should reverse the hypoxia of tissue. According to the recent Nobel Laureates, diseases including stroke, heart attacks, and cancer are associated with large regions of hypoxic tissue operating at low metabolic levels that need oxygen to switch them back to normal function. In theory, BXT-25 could effectively target these indications.
Strokes effects over 900,000 people per year and the indirect costs of stroke due to disability and special services are over $22 billion annually. The standard of care in stroke has remained relatively unchanged for the past 10 years. Since no treatment exists for first responders to get oxygen to the affected parts of the brain, the emphasis had been on awareness and quickly routing patients to stroke treatment centers.
Almost all stroke treatment starts with diagnosing between an ischemic or hemorrhagic stroke. Ischemic stroke are more common and happen in 87% of the stroke victims. It is estimated that patients spend 2.5 hours from the onset of stroke until they can get Tissue Plasminogen activator (tPA) treatment for ischemic strokes to remove the blockage and restore the oxygen supply to the brain. If a hemorrhagic stroke patient were given tPA it would be fatal, which is the rationale behind imaging first. This standard of care comes at a cost because many ischemic stroke patient are becoming impaired while they get their imaging diagnosis. BXT-25 serves as an oxygen bridge for the stroke victim until they can get the correct type of treatment. Bioxytran is addressing a huge unmet medical need that could virtually eliminate the restorative care and rehabilitation needed after a stroke.
BioXyTran, Inc.’s management team has a successful track record in the biotech and pharmaceutical arena, with decades of collective experience. For more information, visit http://www.Bioxytraninc.com.